CrushSCI.com
156.7平均天数
141.5中位天数
24最短天数
350最长天数
2892025发文量

Paper Review Records

全部论文审稿周期

20 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

172 天

Stem cell source, CD34+ dose and outcomes in haploidentical hematopoietic cell transplantation for myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

作者
Tomasz Czerw; Luuk Gras; Laurien GA Baaij; Massimiliano Gambella; Didier Blaise; Patrizia Chiusolo; Mi Kwon; Jakob Passweg; Alessandro Busca; Sandrine Loron; Patrice Ceballos; Mohamad Mohty; Fabio Ciceri; Radovan Vrhovac; Antonio Bianchessi; Matteo Parma; Hakan Ozdogu; Johannes Clausen; Linda Koster; Joanna Drozd-Sokolowska; Kavita Raj; Giorgia Battipaglia; Nicola Polverelli; Donal P. McLornan; Juan Carlos Hernández-Boluda展开收起
作者单位
1. Maria Skłodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland; 2. EBMT Leiden Study Unit, Leiden, the Netherlands; 3. IRCCS Ospedale Policlinico San Martino, Genova, Italy; 4. Programme de Transplantation & Therapie Cellulaire, Marseille, France; 5. Dipartimento di Scienze di Laboratorio ed Ematologiche-Fondazione Policlinico Universitario Agostino Gemelli IRCCS-Università Cattolica del Sacro Cuore-, Roma, Italy; 6. Hospital Gregorio Marañón, Madrid, Spain; 7. University Hospital Basel, Basel, Switzerland; 8. S.S.C.V.D Trapianto di Cellule Staminali, Torino, Italy; 9. Centre Hospitalier Lyon Sud, Lyon, France; 10. CHU Lapeyronie, Montpellier, France; 11. Hopital Saint Antoine, Paris, France; 12. Ospedale San Raffaele s.r.l, Milano, Italy; 13. University Hospital Centre Zagreb, Zagreb, Croatia; 14. Unit of Bone Marrow Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 15. Ospedale San Gerardo, Monza, Italy; 16. Baskent University Hospital, Adana, Turkey; 17. Elisabethinen-Hospital, Linz, Austria; 18. Central Clinical Hospital, The Medical University of Warsaw, Warsaw, Poland; 19. University College London Hospitals NHS Trust, London, UK; 20. Hematology Department, Federico II University of Naples, Naples, Italy; 21. Department of Hematology, Hospital Clínico Universitario, Valencia, Spain展开收起
PDF源文件 DOI 网页
131 天

Optimal levetiracetam dosage regimen for preventing seizures related to immune effector cell-associated neurotoxicity syndrome

作者
Yuri Sugimoto; Yuichi Tsuchiya; Yudai Wada; Nanae Yamamoto; Hoyumi Uematsu; Daisuke Kobayashi; Takuji Yamauchi; Fumiaki Jinnouchi; Teppei Sakoda; Kohta Miyawaki; Takahiro Shima; Ken Takigawa; Masatoshi Shimo; Yoshikane Kikushige; Yasuo Mori; Satoshi Nakao; Takahiro Nakamura; Masatoshi Mine; Koichi Akashi; Takeshi Hirota; Mayako Uchida; Koji Kato展开收起
作者单位
1. Department of Pharmacy, Kyushu University Hospital, Higashi-ku, Japan; 2. Department of Clinical Pharmacology and Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Japan; 3. Department of Clinical Pharmacy and Pharmaceutical Care, Graduate School of Pharmaceutical Sciences, Kyushu University, Higashi-ku, Japan; 4. Department of Hematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Higashi-ku, Japan展开收起
PDF源文件 DOI 网页
95 天

Bridging to CD19 CAR T-cell therapy for large B-cell lymphoma: An analysis of 1,134 patients by the EBMT Lymphoma Working Party and the GoCART Coalition

作者
Philipp Berning; Christophe Peczynski; Jan C. Schroeder; Eva Michel; Michael Oertel; Fizza Imran; Evgenii Shumilov; Imke E. Karsten; Robin Sanderson; Urban Novak; Ron Ram; Peter Dreger; David Beauvais; Maxime Delforge; Daniela Taurino; Robin Noel; Almudena Cabero; Ralph Wäsch; Malte von Bonin; Peter Vandenberghe; Olaf Penack; Björn Chapuy; Avichai Shimoni; Barbara Dreta; Ulf Schnetzke; Eugenio Galli; Anna Ossami Saidy; Georg Lenz; Bertram Glass; Anna Sureda; Ali Bazarbachi; Wolfgang Bethge; Norbert Schmitz展开收起
作者单位
1. Department of Medicine A, University Hospital Münster, Münster, Germany; 2. European Society for Blood and Marrow Transplantation, Paris Office, Paris, France; 3. University Hospital and Comprehensive Cancer Center Tübingen, Department for Hematology, Oncology, Clinical Immunology and Rheumatology, Tübingen, Germany; 4. Department of Radiation Oncology, University Hospital Münster, Münster, Germany; 5. King’s College Hospital, London, UK; 6. Department of Medical Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland; 7. BMT Unit, Tel Aviv Sourasky Medical Center and Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel; 8. University of Heidelberg, Heidelberg, Germany; 9. Department of Hematology, CHU Lille, Lille, France; 10. IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milano, Rozzano, Milano, Italy; 11. Programme de Transplantation & Thérapie Cellulaire, Marseille, France; 12. Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), Salamanca, Spain; 13. University of Freiburg, Freiburg, Germany; 14. Universitätsklinikum Dresden, Dresden, Germany; 15. University Hospitals Leuven, Leuven, Belgium; 16. Department of Hematology, Oncology, and Cancer Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany; 17. German Cancer Consortium, partner site Berlin, a partnership between German Cancer Consortium and Charité-Universitätsmedizin Berlin, Berlin, Germany; 18. Chaim Sheba Medical Center, Tel-Hashomer, Israel; 19. University Hospital Center Rebro, Zagreb, Croatia; 20. Department of Hematology and Medical Oncology, University Hospital Jena, Jena, Germany; 21. Dipartimento di Scienze di laboratorio ed ematologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 22. Helios Klinikum Berlin-Buch, Berlin, Germany; 23. Hematology Department, Institut Català d’Oncologia, Barcelona-L’Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; 24. Bone Marrow Transplantation Program, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon展开收起
PDF源文件 DOI 网页
350 天

Outcomes of autologous cord blood transplantation followed by cyclosporine A monotherapy in pediatric aplastic anemia: A single-center experience and pooled analysis

作者
Chaoqian Jiang; Xia Chen; Luyang Zhang; Yuanyuan Ren; Lipeng Liu; Yue Shang; Xin Wang; Yumei Chen; Li Zhang; Yao Zou; Fang Liu; Xiaojuan Chen; Wenyu Yang; Xiaofan Zhu; Ye Guo展开收起
作者单位
1. Department of Pediatric Hematology and Oncology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China; 2. Tianjin Institutes of Health Science, Tianjin, China展开收起
PDF源文件 DOI 网页
246 天

Cryopreservation of academic CAR T-cell products: methodological recommendations from the EBMT practice harmonisation and guidelines committee

作者
Halvard Bonig; Boris Calmels; Camille Giverne; Ulrike Köhl; Jürgen Kuball; Chantal Lechanteur; Francesco Onida; Isabel Sánchez-Ortega; Annalisa Ruggeri; Trudy Straetemans; Nina Worel; Ibrahim Yakoub-Agha展开收起
作者单位
1. Institute for Transfusion Medicine and Immunohematology, Goethe University and German Red Cross Blood Service BaWueHe, Frankfurt, Germany; 2. Centre de Thérapie Cellulaire, Institut Paoli-Calmettes, INSERM CIC Biothérapie BT-510, Marseille, France; 3. CHU de Rouen, laboratoire d’Immunologie et Biothérapies, Université de Rouen Normandie, INSERM, UMR 1234, Rouen, France; 4. Fraunhofer Institute of Cell therapy and Immunology; Institute of Clinical Immunology, University and University hospital, Leipzig, Germany; 5. Center for Translational Immunology, & Department of Haematology, University Medical Center Utrecht, Utrecht, The Netherlands; 6. Laboratoire de thérapie cellulaire et génique (LTCG), Hématologie Clinique, CHU de Liège, Liège, Belgique; 7. Hematology and BMT Unit, ASST Fatebenefratelli-Sacco, Dept. of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; 8. Co chair of the EBMT Practice Harmonisation Committee, Barcelona, Spain; 9. EBMT Chief Medical Officer, Barcelona, Spain; 10. Secretary of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, Spain; 11. Unit of Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy; 12. Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria; 13. CHU de Lille, Univ Lille, INSERM U1286, Infinite, Lille, France; 14. Chair of the EBMT Practice Harmonisation and Guidelines Committee, Barcelona, Spain展开收起
PDF源文件 DOI 网页
94 天

Pre-transplant IFD history influences the incidence of IFD after allogeneic haematopoietic stem cell transplantation

作者
Danping Zhu; Liyun Chen; Xiaoyu Zhu; Nainong Li; Weijie Cao; Zhongming Zhang; Yehui Tan; Xiaoxia Hu; Hailong Yuan; Xiaosheng Fang; Yue Yin; Hongtao Wang; Xiaojun Huang; Jia Chen; Yuqian Sun展开收起
作者单位
1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China; 2. Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; 3. Department of Hematology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, China; 4. Department of Hematology, Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China; 5. Department of Hematology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; 6. Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China; 7. Department of Hematology, The First Affiliated Hospital of Jilin University, Changchun, China; 8. State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 9. The First Affiliated Hospital of Xinjiang Medical University, Xinjiang Institute of Hematology, Urumqi, China; 10. Department of Hematology, Shandong First Medical University Affiliated Provincial Hospital, Jinan, China; 11. Department of Hematology, Peking University First Hospital, Beijing, China; 12. Department of Hematology, Shengjing Hospital of China Medical University, Shenyang, China展开收起
PDF源文件 DOI 网页

FAQ

BONE MARROW TRANSPLANTATION审稿要多久?

截至2026-11-18,CrushSCI 收录了 BONE MARROW TRANSPLANTATION 的 20 篇完整审稿记录。最快一篇从收稿到录用用了 24 天(PTCy-based GVHD prophylaxis helps navigate donor selection in secondary AML undergoing alternative donor transplantation,2026-07-20 收稿,2026-08-13 录用),最慢一篇用了 350 天;平均 156.7 天,中位数 141.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。